These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 34649705)
41. Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents. Glikson E; Chavkin U; Madgar O; Sagiv D; Nakache G; Yakirevitch A; Wolf M; Alon EE Laryngoscope; 2019 Jan; 129(1):119-123. PubMed ID: 30325496 [TBL] [Abstract][Full Text] [Related]
42. Major bleeding in a patient with warfarin-hypersensitive and factor IX propeptide variant, p.Ala37Thr, who was treated with a direct oral anti-Xa inhibitor. Tamura A; Wada H; Ikejiri M; Miyata T; Habe K; Tomimoto H Ann Hematol; 2019 Jan; 98(1):209-210. PubMed ID: 29923114 [No Abstract] [Full Text] [Related]
43. Evaluation of Direct Oral Anticoagulants Versus Warfarin for Intracardiac Thromboses. Iskaros O; Marsh K; Papadopoulos J; Manmadhan A; Ahuja T J Cardiovasc Pharmacol; 2021 May; 77(5):621-631. PubMed ID: 33560043 [TBL] [Abstract][Full Text] [Related]
44. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Piccini JP; Garg J; Patel MR; Lokhnygina Y; Goodman SG; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Nessel CC; Mahaffey KW; Singer DE; Califf RM; Fox KA; Eur Heart J; 2014 Jul; 35(28):1873-80. PubMed ID: 24658769 [TBL] [Abstract][Full Text] [Related]
45. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience. Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572 [TBL] [Abstract][Full Text] [Related]
46. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation. Briasoulis A; Mentias A; Mazur A; Alvarez P; Leira EC; Vaughan Sarrazin MS Cardiovasc Drugs Ther; 2021 Apr; 35(2):261-272. PubMed ID: 33404923 [TBL] [Abstract][Full Text] [Related]
47. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. Buller HR; Halperin J; Hankey GJ; Pillion G; Prins MH; Raskob GE J Thromb Haemost; 2014 Jun; 12(6):824-30. PubMed ID: 24597472 [TBL] [Abstract][Full Text] [Related]
48. Drug Treatment of Venous Thromboembolism in the Elderly. Boey JP; Gallus A Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713 [TBL] [Abstract][Full Text] [Related]
49. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052 [TBL] [Abstract][Full Text] [Related]
50. The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation. Fernández CS; Gullón A; Formiga F J Comp Eff Res; 2020 May; 9(7):509-523. PubMed ID: 32329353 [TBL] [Abstract][Full Text] [Related]
51. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905 [TBL] [Abstract][Full Text] [Related]
52. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. Vilain K; Li H; Kwong WJ; Antman EM; Ruff CT; Braunwald E; Cohen DJ; Giugliano RP; Magnuson EA; Circ Cardiovasc Qual Outcomes; 2020 Nov; 13(11):e006511. PubMed ID: 33148013 [TBL] [Abstract][Full Text] [Related]
53. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight. Perales IJ; San Agustin K; DeAngelo J; Campbell AM Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028 [No Abstract] [Full Text] [Related]
54. Pericardial bleeding risk with non-vitamin K oral anticoagulants: a meta-analysis. Caldeira D; Barra M; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J Int J Cardiol; 2015 Mar; 182():187-8. PubMed ID: 25577761 [No Abstract] [Full Text] [Related]
55. Antidotes for reversal of direct oral anticoagulants. Dobesh PP; Bhatt SH; Trujillo TC; Glaubius K Pharmacol Ther; 2019 Dec; 204():107405. PubMed ID: 31521696 [TBL] [Abstract][Full Text] [Related]
56. Changing Treatment Patterns in Patients With Venous Thromboembolism in Taiwan. Lee CH; Fang CC; Tsai LM; Lin HW; Chen PS; Lin SH; Li YH Circ J; 2020 Jan; 84(2):283-293. PubMed ID: 31932560 [TBL] [Abstract][Full Text] [Related]
57. New oral anticoagulant-induced bleeding: clinical presentation and management. Levy JH; Levi M Clin Lab Med; 2014 Sep; 34(3):575-86. PubMed ID: 25168943 [TBL] [Abstract][Full Text] [Related]
58. Perioperative Management of Direct Oral Anticoagulants in Cardiac Surgery: Practice Recommendations Based on Current Evidence. Budd AN; Wood B; Zheng W; Rong LQ J Cardiothorac Vasc Anesth; 2022 Nov; 36(11):4141-4149. PubMed ID: 35965231 [TBL] [Abstract][Full Text] [Related]
59. Preoperative management of anticoagulation in the surgical patient: Highlights of the latest guidelines. Elgamal H; Luedi MM; Ender JK; Meineri M Best Pract Res Clin Anaesthesiol; 2020 Jun; 34(2):141-152. PubMed ID: 32711825 [TBL] [Abstract][Full Text] [Related]
60. Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation. McCarty D; Robinson A Ther Adv Cardiovasc Dis; 2016 Feb; 10(1):37-49. PubMed ID: 26378211 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]